NCT01560286View on ClinicalTrials.gov

A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

July 31, 2015

Conditions
Phenylketonuria
Interventions
BIOLOGICAL

BMN 165 (rAvPAL-PEG)

Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.

Trial Locations (6)

12208

Albany Medical Center, Albany

32610

University of Florida, Gainesville, Gainesville

68198

Nebraska Medical Center, Omaha

80048

The Children's Hospital, Aurora

84132

University of Utah Hospital, Salt Lake City

02115

Children's Hospital Boston, Boston

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY